EyeGate Pharmaceuticals, Inc. Forecast, price target & analysts
EyeGate Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
EyeGate Pharmaceuticals, Inc. Classifications & Recommendation:
EyeGate Pharmaceuticals, Inc. Price Target
| Target Price | $18.50 |
| Price | $3.25 |
| Potential |
469.23%
register free of charge
|
| Number of Estimates | 2 |
|
2 Analysts have issued a price target EyeGate Pharmaceuticals, Inc. 2026 .
The average EyeGate Pharmaceuticals, Inc. target price is $18.50.
This is
469.23%
register free of charge
$27.00
730.77%
register free of charge
$10.00
207.69%
register free of charge
|
|
| A rating was issued by 2 analysts: 2 Analysts recommend EyeGate Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the EyeGate Pharmaceuticals, Inc. stock has an average upside potential 2026 of
469.23%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 16.76 |
2 Analysts have issued a sales forecast EyeGate Pharmaceuticals, Inc. 2024 . The average EyeGate Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued a net profit forecast EyeGate Pharmaceuticals, Inc. 2024 . The average EyeGate Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -24.25 | 0.45 |
| 85.47% | 101.86% | |
| P/E | 7.24 | |
| EV/Sales | negative |
1 Analysts have issued a EyeGate Pharmaceuticals, Inc. forecast for earnings per share. The average EyeGate Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the EyeGate Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
EyeGate Pharmaceuticals, Inc....
Current EyeGate Pharmaceuticals, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 12 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
